Andrew Wilkins > Dechert LLP > Boston, United States > Lawyer Profile
Dechert LLP Offices
ONE INTERNATIONAL PLACE
40TH FLOOR, 100 OLIVER STREET
MA 02110-2605
United States
- Firm Profile
- Go to...
Andrew Wilkins
Work Department
Intellectual Property
Position
Partner
Career
Andrew T. Wilkins, Ph.D. is a partner in Dechert’s intellectual property group, focusing his practice on patent law relating to biotechnology. Dr. Wilkins has extensive experience representing biotech companies and investors in strategic international patent portfolio development and life cycle management, as well as non-infringement and invalidity analysis, post-grant proceedings and IP due diligence.
Dr. Wilkins has advised clients on matters relating to an array of biotech areas, including: therapeutic antibodies and antibody-like molecules for oncology, autoimmune, cardiovascular and infectious disease indications; immunotherapy, including CAR and recombinant TCR technologies, peptide-based vaccines and immune checkpoint antibodies; antibody and TCR discovery and engineering technologies; glycoengineering technologies, including antibody Fc glycoengineering technologies; viral delivery technologies, including lentiviral and AAV delivery technologies; gene therapy technologies, including gene replacement and gene editing technologies; biocompatible drug delivery vehicles, including controlled release nanoparticle liposome technologies; drug screening assays; RNAi technologies; and Bayh-Dole compliance in the acquisition or licensing of IP based upon NIH-funded research.
In addition to his practice, Dr. Wilkins has prolific academic and industrial research experience, his previous roles including: an instructor in medicine at Harvard Medical School/Beth Israel Deaconess Medical Center in Boston; a graduate research student with GlaxoSmithKline, UK; a postdoctoral research associate with MRC Laboratory of Molecular Biology, UK; and an undergraduate research student with Celltech PLC, UK. He has authored/co-authored numerous scientific articles in top peer-reviewed journals, such as Genes and Development, Current Biology, Biochemical Journal, Genome Biology, Cell Motility and the Cytoskeleton, Trends in Genetics and Methods in Enzymology.
Education
- University of Glasgow, B.Sc., Biochemistry
- University of London, Ph.D., Molecular Cell Biology
- Suffolk University Law School, J.D.
Lawyer Rankings
United States > Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
The Boston-based team at Dechert has notable capabilities advising its clientele on the patent-related aspects that underpin significant financial transactions. Further, it handles strategy, prosecution, and implementation elements of various patents. Andrea Reid and Andrew Wilkins co-head the offering; Reid has expertise in life sciences matters while Wilkins specializes in the management of portfolios relating to large molecules. Chad Davis‘ workload includes handling IP risk assessments, due diligence aspects, and the handling of the prosecution and development of patent portfolios. John Rearick also advises on patent due diligence, particularly in the life sciences space.
Lawyer Rankings
Top Tier Firm Rankings
- Environment > Environment: transactional
- International trade and national security > Customs, export controls and economic sanctions
- Dispute resolution > International arbitration
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- International trade and national security > Customs, export controls and economic sanctions
- Real estate > Real estate finance
- Finance > Structured finance: securitization
Firm Rankings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Healthcare > Life sciences
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Dispute resolution > Securities litigation: defense
- Antitrust > Civil litigation/class actions: defense
- Finance > Commercial lending > Advice to direct lenders/private credit
- Dispute resolution > E-discovery
- Dispute resolution > General commercial disputes
- Dispute resolution > International litigation
- Dispute resolution > M&A litigation: defense
- Antitrust > Merger control
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Finance > Restructuring (including bankruptcy): corporate
- Tax > US taxes: non-contentious
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- International trade and national security > CFIUS
- Finance > Commercial lending
- International trade and national security > Customs, export controls and economic sanctions
- Dispute resolution > Financial services litigation
- Finance > Fintech
- Dispute resolution > International arbitration
- Tax > International tax
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Intellectual property > Patents: litigation (full coverage)
- Finance > Capital markets: high-yield debt offerings
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)